Top ▲
GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
Gene and Protein Information ![]() |
||||||
| Species | TM | AA | Chromosomal Location | Gene Symbol | Gene Name | Reference |
| Human | - | 61 | 1p36.11 | CD52 | CD52 molecule | |
| Mouse | - | 74 | 4 66.5 cM | Cd52 | CD52 antigen | |
| Rat | - | 96 | 5q36 | Cd52 | CD52 molecule | |
Previous and Unofficial Names ![]() |
| CAMPATH-1 antigen | myeloid cell surface antigen CD33 |
Database Links ![]() |
|
| Alphafold | P31358 (Hs), Q64389 (Mm), Q63064 (Rn) |
| ChEMBL Target | CHEMBL1912 (Hs) |
| DrugBank Target | P31358 (Hs) |
| Ensembl Gene | ENSG00000169442 (Hs), ENSMUSG00000000682 (Mm), ENSRNOG00000015403 (Rn) |
| Entrez Gene | 1043 (Hs), 23833 (Mm), 117054 (Rn) |
| Human Protein Atlas | ENSG00000169442 (Hs) |
| KEGG Gene | hsa:1043 (Hs), mmu:23833 (Mm), rno:117054 (Rn) |
| OMIM | 114280 (Hs) |
| Pharos | P31358 (Hs) |
| RefSeq Nucleotide | NM_001803 (Hs), NM_013706 (Mm), NM_053983 (Rn) |
| RefSeq Protein | NP_001794 (Hs), NP_038734 (Mm), NP_446435 (Rn) |
| UniProtKB | P31358 (Hs), Q64389 (Mm), Q63064 (Rn) |
| Wikipedia | CD52 (Hs) |
Download all structure-activity data for this target as a CSV file
| Antibodies | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Key to terms and symbols | Click column headers to sort | ||||||||||||||||||||||||||||||||||||||||||||||||||
|
|||||||||||||||||||||||||||||||||||||||||||||||||||
| Antibody Comments | |||||||||||||||||||||||||||||||||||||||||||||||||||
| The anti-CD52 antibody GZ-402668 (GLD52; gatralimab) was developed by Sanofi for the treament of progressive multiple sclerosis. Having completed Phase 1 evaluation, Sanofi halted further development of this agent in early 2018. | |||||||||||||||||||||||||||||||||||||||||||||||||||
| Immunopharmacology Comments |
| CD52 (CAMPATH-1) is a short, glycosylphosphatidylinositol (GPI) anchored peptide expressed on lymphocytes and by cells of the male genital tract. CD52 is required for complement-mediated cell lysis and antibody-mediated cellular cytotoxicity. The approved monoclonal antibody, alemtuzumab targets this function of CD52. By attaching to sperm it may be associated with oocyte penetration and fertilisation. |
| Cell Type Associations | ||||
|
||||
|
||||
|
||||
|
1. Ginaldi L, De Martinis M, Matutes E, Farahat N, Morilla R, Dyer MJ, Catovsky D. (1998) Levels of expression of CD52 in normal and leukemic B and T cells: correlation with in vivo therapeutic responses to Campath-1H. Leuk Res, 22 (2): 185-91. [PMID:9593475]
2. Shitara K, Niwa R, Natsume A. (2011) Recombinant antibody composition. Patent number: US7923538 B2. Assignee: Kyowa Hakko Kirin Co., Ltd. Priority date: 22/07/2005. Publication date: 12/04/2011.
CD molecules: CD52. Last modified on 22/10/2019. Accessed on 03/11/2025. IUPHAR/BPS Guide to PHARMACOLOGY, https://www.guidetoimmunopharmacology.org/GRAC/ObjectDisplayForward?objectId=2602.